Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Updated on 26 May 2022


This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of ssCART-19 in the treatment of patients with CD19 positive relapsed or refractory acute lymphoblastic leukemia.


This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of ssCART-19 in the treatment of patients with CD19 positive relapsed or refractory acute lymphoblastic leukemia.

Primary objectives:

Determine the safety and tolerability of ssCART-19 cells in patients with refractory or relapsed acute lymphoblastic leukemia.

Secondary objectives:

  1. Observe the anti-tumor response of ssCART-19 cells to refractory or relapsed acute lymphoblastic leukemia.
    • Overall remission rate (ORR) assessment during the 3 months after ssCART-19 administration,ORR includes CR and CRi
    • Duration of response (DOR)
    • Progression-free survival (PFS)
    • Overall survival (OS)
  2. To characterize the in vivo cellular pharmacokinetic (PK) profile of ssCART-19 cells.
  3. To characterize the pharmacodynamic (PD) profile of ssCART-19 cells.

Condition Relapsed or Refractory Acute Lymphoblastic Leukemia
Treatment cyclophosphamide, Fludarabine, ssCART-19 Cells
Clinical Study IdentifierNCT04825496
SponsorShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Last Modified on26 May 2022


Yes No Not Sure

Inclusion Criteria

Relapsed or refractory acute lymphoblastic leukemia (ALL):(1)Any Relaps after first remission OR (2)Any BM relapse after allogeneic SCT and must be ≥ 3 months from SCT at the time of ssCART-19 infusion OR (3)failed to reach CR after 2 cycles of induction chemotherapy regimen OR (4)Patients with Ph+ ALL are eligible if they are intolerant to or have failed two lines of TKI therapy, or if TKI therapy is contraindicated
CD19 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry
Bone marrow with ≥ 5% lymphoblasts by morphologic assessment
Adequate organ function defined as:(1)left ventricular ejection fraction ≥ 50% by echocardiogram;(2)creatinine ≤ 1.6mg/dl;(3)ALT and AST≤3 times the ULN for age, total bilirubin ≤ 2.0mg/dl;(4)Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation > 91% on room air
Informed consent is signed by the subject
Age 18 to 65
Fertility of men, to ensure that sexual partners can effectively contraception; Women with fertility use effective contraceptive measures and agree to use contraceptive measures throughout the study period
Qualified T cell amplification
Eastern cooperative oncology group (ECOG) performance status of 0 to 1
Vascular conditions for apheresis
The estimated survival time is more than 3 months

Exclusion Criteria

Isolated extra-medullary disease relapse
Combined with other malignant tumors
Has had treatment with any prior anti-CD19/anti-CD3 therapy, or any other antiCD19 therapy
Has had immunosuppressants or hormones within 2 weeks before signing informed consent, or plan to use immunosuppressants or hormones after signing informed consent
Patients complying with any of hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg) positive, hepatitis B e antibody (HBe-Ab) and/or hepatitis B core antibody (HBc-Ab) positive and HBV-DNA copies being more than the lower limit of detection, hepatitis C antibody (HCV-Ab) positive, anti-treponemia pallidum antibody (TP-Ab) positive, EBV-DNA, and CMV-DNA copies being more than the lower limit of detection
Has uncontrolled bacteria, fungi, viruses, mycoplasma or other types of infections
Infected with HIV, syphilis or COVID-19
Has a history of severe immediate hypersensitivity to aminoglycosides
Has past or present CNS diseases, such as epilepsy, cerebrovascular ischemia/hemorrhage, dementia, cerebellar diseases or any CNS-related autoimmune diseases
Has undergone cardiac angioplasty or stent implantation within 12 months before signing informed consent, or having a history of myocardial infarction, unstable angina pectoris or other clinically significant heart diseases
With primary immunodeficiency
Has had severe immediate hypersensitivity reaction to any drug to be used in this study
Has had treat with live vaccine within 6 weeks prior to screening
Pregnant or lactating women
Has active autoimmune diseases
Has active acute or chronic graft-versus-host disease (GVHD) before signing informed consent
Patient has an investigational medicinal product within 3 months before signing informed consent
Patients with other conditions making the patients unsuitable for receiving cell therapy as judged by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note